Day 3 Program

FDA Session: HR+ Metastatic Breast Cancer in 2025—Progress, Regulatory Approvals, and the Trials Ahead

Day 3: December 11, 2025

4:30 PM–6:00 PM CST

Session Details

Moderator

Angela DeMichele, University of Pennsylvania, Philadelphia, PA

Designing Clinical Trials in HR+ Metastatic Breast Cancer: Navigating a Crowded Therapeutic Landscape

Angela DeMichele, University of Pennsylvania, Philadelphia, PA